Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US81663L2007
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XDHY5P9
WGS
GeneDx Holdings Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $GRLZ
NAME
GeneDx Holdings Corp
ISIN
US81663L2007
TICKER
WGS
MIC
XNAS
REUTERS
WGS.OQ
BLOOMBERG
WGS US
Tue, 09.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 9, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 16...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

NEW YORK, June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff a...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosi...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       GeneDx
US81663L2007

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purc...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       GeneDx
US81663L2007

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.06.2026       GeneDx
US81663L2007

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 06.06.2026       GeneDx
US81663L2007

NEW YORK, June 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A cla...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 06.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 06.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Sat, 06.06.2026       GeneDx
US81663L2007

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026. GeneDx describes itself as an “American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing and whol...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       GeneDx
US81663L2007

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. In...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 5, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 16...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.06.2026       GeneDx
US81663L2007

SAN DIEGO, June 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), have until August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. Gen...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       GeneDx
US81663L2007

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosing pediatric and rare diseases. For mo...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 04.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 mill...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.This press re...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       GeneDx
US81663L2007

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 mill...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami, FL. Management will participate in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       GeneDx
US81663L2007

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       GeneDx
US81663L2007

GeneDx posted Q1 2026 revenue of $102.3 million against consensus estimates near $110 million and reported adjusted EPS of -$0.28 versus the -$0.01 expected -- the stock collapsed approximately 44% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders who held GeneDx Holdings Corp. (NASDAQ: WGS) stock lost approximately 44% of...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) ("GeneDx Holdings Corp.") concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       GeneDx
US81663L2007

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       GeneDx
US81663L2007

GeneDx CFO promised quarterly profitability weeks before the company posted an $8.2 million adjusted loss -- and then cut full-year guidance by approximately 12%. NEW YORK, May 13, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) lost approximately 44% of their share value after Q1 2026 earnings revealed a significant revenue...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       GeneDx
US81663L2007

Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit ht...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.05.2026       GeneDx
US81663L2007

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 7, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the c...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       GeneDx
US81663L2007

The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVES...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       GeneDx
US81663L2007

Boston, Massachusetts--(Newsfile Corp. - May 6, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit htt...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       GeneDx
US81663L2007

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENE...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       GeneDx
US81663L2007

Law Offices of Howard G. Smith announces an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GENEDX HOLDINGS CORP. (WGS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTEN...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       GeneDx
US81663L2007

The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM T...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       GeneDx
US81663L2007

MILWAUKEE, May 5, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against GeneDx (Nasdaq: WGS). The investigation results from inaccurate statements GeneDx may have made regarding its financial statements, business operations and prospects....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026. “GeneDx delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that there’s sustained, strong d...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating resu...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-P...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two ra...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       GeneDx
US81663L2007

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Boston, MA Fireside Chat: Monday, March 2 at 1:50 p.m. ET Barclays 28th Annual Global H...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       GeneDx
US81663L2007

Insert the "Software and interpretation services" row in the Volume & Revenue(1) table. The updated release reads: GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026 GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025. “The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is unique...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME’s annual recognition of the 100 individuals who most influenced global health over the past year....
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30...
Read more
GeneDx
Technical Analysis Termsheets Terminal
Permalink